Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience |
| |
| Authors: | Maria K Angelopoulou Theodoros P Vassilakopoulos Ioannis Batsis Ioanna Sakellari Konstantinos Gkirkas Vasiliki Pappa Panagiota Giannoulia Ioannis Apostolidis Christos Apostolopoulos Paraskevi Roussou Panayiotis Panayiotidis Maria Dimou Marie‐Christine Kyrtsonis Maria Palassopoulou Georgios Vassilopoulos Maria Moschogiannis Christina Kalpadakis Dimitrios Margaritis Alexander Spyridonidis Eurydiki Michalis Konstantinos Anargyrou Panagiotis Repousis Eleutheria Hatzimichael Zoi Bousiou Elias Poulakidas Dimitrios Grentzelias Nikolaos Harhalakis Gerassimos A Pangalis Achilles Anagnostopoulos Panagiotis Tsirigotis |
| |
| Institution: | 1. Department of Hematology, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece;2. Hematology and Bone Marrow Transplantation Department, General Hospital of Thessaloniki Papanikolaou, Thessaloniki, Greece;3. 2nd Department of Internal Medicine, Faculty of Medicine, ATTIKON General University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece;4. Department of Hematology, Evaggelismos General Hospital, Athens, Greece;5. Third Department of Medicine, “Sotiria” General Hospital of Thoracic Diseases, Hematology Unit, National and Kapodistrian University of Athens, Medical School, Athens, Greece;6. 1st Department of Propedeutic Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece;7. Department of Hematology, Larissa University Hospital, University of Thessalia, Larissa, Greece;8. Department of Hematology, Athens Medical Center, Athens, Greece;9. Department of Hematology, Heraklion University Hospital, University of Crete, Heraklion, Greece;10. Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece;11. Bone Marrow Transplantation Unit, University of Patras, Patras, Greece;12. Department of Clinical Hematology, “G.Gennimatas” Athens General Hospital, Athens, Greece;13. Department of Hematology, Air Force Hospital, Athens, Greece;14. Department of Hematology, Metaxa Hospital, Pireaus, Greece;15. Department of Hematology, Ioannina University Hospital, University of Ioannina, Ioannina, Greece;16. Department of Hematology, 401 Military Hospital of Athens, Athens, Greece;17. Hygeia General Hospital, Athens, Greece |
| |
| Abstract: | This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety‐five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty‐seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the patients were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2‐16), and the median time to best response was the fourth cycle. Fifty‐seven patients achieved an objective response: twenty‐two (23%), a complete response (CR), and 35 patients (37%), a partial, for an overall response rate of 60%. Twelve patients (13%) had stable disease, and the remaining twenty‐six (27%) had progressive disease as their best response. At a median follow‐up of 11.5 months, median progression‐free survival and overall survival were 8 and 26.5 months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV (P = .005). Bulky disease (P = .01) and response to BV (P <.001) were significant for progression‐free survival, while refractoriness to most recent treatment (P = .04), bulky disease (P = .005), and B‐symptoms (P = .001) were unfavorable factors for overall survival. Among the 22 CRs, 5 remain in CR with no further treatment after BV at a median follow‐up of 13 months. In conclusion, our data indicate that BV is an effective treatment for R/R HL patients even outside clinical trials. Whether BV can cure a fraction of patients remains to be seen. |
| |
| Keywords: | autologous stem cell transplantation brentuximab vedotin Hodgkin lymphoma prognostic factors relapsed/refractory |
|
|
